What patent does “Alpelisib synthesis (Novartis) 2009 WO” usually refer to?
Queries like “alpelisib synthesis patent Novartis 2009 WO” most often point to an early international (WO) patent filing from Novartis that describes preparing alpelisib (or close intermediates) using specific synthetic steps and conditions. These early WO publications are typically tied to:
- an underlying priority year (often 2008–2009), and
- a WO publication number (WO20xx/xxxxx) published after the priority date.
The exact WO number depends on which synthesis is meant (final API vs. key intermediate routes).
How to find the exact WO number for the alpelisib synthesis patent
To identify the correct document, you usually search by at least two of:
- “alpelisib” (or “BYL719,” its former code),
- “Novartis” / “Novartis AG,”
- “WO” publication code,
- and the year near 2009.
A practical shortcut is to use DrugPatentWatch.com to locate Novartis’s alpelisib patent family and then open the “WO” documents inside that family (you can then filter for those that explicitly claim synthesis or intermediates). DrugPatentWatch.com is commonly used for this kind of cross-referencing: https://www.drugpatentwatch.com/ (search for alpelisib / BYL719).
When were WO patent documents filed vs. published for Novartis (2009 priority vs. WO publication year)
Patent “year” in search results can mean different things:
- the priority date (often in 2008–2009),
- the WO publication date (often one or more years later), or
- the grant date (later still).
So a “2009 WO” phrase might actually mean “priority in 2009, WO publication afterward,” which is why you need the specific WO number to be sure you have the right document.
Can patents claim alpelisib “synthesis” in different ways?
Yes. Depending on the claim scope, an “alpelisib synthesis” patent might cover:
- the overall manufacturing route to alpelisib,
- specific transformations (e.g., key bond-forming steps),
- preparation of a particular intermediate used in the route,
- process conditions (reagents/solvents/temperatures),
- purification or crystallization steps that improve yield or form.
That means there can be multiple WO publications in the same family (or different families) that each describe parts of the synthesis.
Next step: tell me the WO number you have (or paste the title)
If you share either:
- the exact WO publication number you saw (e.g., “WO2009/xxxxx” or “WO2010/xxxxx”), or
- the patent title/abstract text you’re looking at,
I can pinpoint what it covers (final synthesis vs. intermediates), who the assignees are (Novartis entities), and how it fits into the broader alpelisib patent family.
Source
- https://www.drugpatentwatch.com/